BioTechnique is a clinical-stage oncolytics company that is focused on discovering and developing novel therapies to treat patients with cancer. Using a next generation nanotechnology drug delivery platform, the company is developing therapies designed to reduce adverse effects associated with traditional chemotherapies and provide a targeted delivery to the tumor location. We are now raising capital to allow us to expand. We are welcoming accredited investors for our second private placement. Our private placement is being managed by Victor Cuilic of Uplift Partners at email@example.com. Please contact our CEO, Mr. John Clapham, for more details regarding this private placement at +1 (626) 786-7035, or jclapham@BioTechnique.com. All private placements shall comply with the US Securities Exchange Commission (SEC) regulations.
- How aspirin and omega-3 may reduce cancer risk November 20, 2018A new clinical trial suggests that taking aspirin and an omega-3 fatty acid can decrease the number of precancerous growths in the colon.
- What are the benefits of flaxseed oil? November 20, 2018Learn about the health benefits of flaxseed oil, such as improved skin and cholesterol, decreased inflammation, and a reduced risk of diabetes. We also cover the potential risks of flaxseed oil, as well as how to use it.
- What does it mean to have stage 4 pancreatic cancer? November 19, 2018When pancreatic cancer has spread to other parts of the body, it is in stage 4. There is no cure for this type of cancer, but treatments can help improve life expectancy and the quality of life. Learn more here.
- How does a doctor diagnose cancer? November 16, 2018Cancer is a common disease, and a whole range of outlooks is possible depending on the type and severity. Knowing how recognize and diagnose cancer early on can be the key to improving the outlook. Read on to learn ,pre about the symptoms and diagnostic techniques saving lives every day.
- Pancreatic cancer cells are 'addicted' to key protein November 14, 2018New research on highly aggressive pancreatic cancers finds that a protein fuels cancer cells to the extent that they become 'addicted' to it.